Author

Yishan Ma

Chinese Academy of Sciences

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Jingsheng CaiiD· 2 shared Mantang QiuiD· 2 shared Xiaonan HuangiD· 2 shared Yufei XiaiD· 2 shared Fuping YouiD· 1 shared G LiD· 1 shared Guanghui Ma· 1 shared J Chen· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Jingsheng CaiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An adjuvant for in vivo CAR-T therapy potentiation against solid tumors

Yu Sun, Yishan Ma, Tong Guan, Yumeng Yan, Yali Ming, Xiaonan Huang, Yujie Luo, Jingsheng Cai, Guanghui Ma, Fuping You, Mantang Qiu, Jingyi Chen, Yufei Xia

This paper introduces an adjuvant (iCTA) that enhances in vivo CAR-T therapy against solid tumors by improving T-cell recruitment, antigen presentation, and tumor microenvironment.

bioRxiv · Nov 2, 2026 · PreprintBioengineering

In vivo programming of stem-like CAR T cells by lymphatic-selective lipid nanoparticle enables durable anti-tumour efficacy in orthotopic model

Yishan Ma, J Chen, Xiaonan Huang, Jingsheng Cai, G L, Mantang Qiu, Yufei Xia

This paper develops a lipid nanoparticle strategy to enhance CAR-T cell persistence and antitumour efficacy in solid tumours by targeting primary lymphoid tissues.

bioRxiv · May 12, 2026 · PreprintBioengineering